Reading Time: 6 minutesOn 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Category: Treatments
Reading Time: 5 minutesIn this guest blog written by Harry Bowles and Sarah Opie-Martin from King’s College London they discuss their MND research poster which was presented at
Reading Time: 5 minutesEach year, the 21st of June marks Global MND Awareness Day and MND Charites and Associations across the world acknowledge the impact that MND has
Reading Time: 6 minutesUpdate 21/09/2022: The results of the VALOR trial and its open label extension were published in the New England Journal of Medicine. These results give
Reading Time: 6 minutesThis year is set to be an exciting time for MND research, and we are especially hopeful that MND clinical trials will take centre stage
Reading Time: 7 minutesLast month saw the two-year anniversary since the first COVID lockdown in England (the UK) which changed our lives forever – not least because of
32nd Symposium: Virtual 32nd Symposium: Virtual Clinical Trials MND Research Research we fund Symposium Treatments
Symposium Spotlight: A closer look at IMODALS clinical trial outcomes
Reading Time: 6 minutesAs the research team are starting to get stuck into planning our next International Symposium on ALS/MND we are taking a look back at some
Reading Time: 5 minutesThis is a guest blog written by Danielle Boyce, DPA, MPH, Executive Director, the Robert Packard Center for ALS Research and Answer ALS Research Program;
Reading Time: 4 minutesResearchers at King’s College London led by Professor Christopher Shaw, are the first in Europe to embark on a clinical trial targeting a specific genetic
Reading Time: 4 minutesThis is blog number 21 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond